Clinical Trial

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is a multicenter, open-label, single-arm, Phase II Study. Patients with CD20 positive recurrent or refractory diffuse large B-cell lymphoma and had failed ≥2 prior lines of standard treatment will be recruited. The purpose of this trial is to evaluate the efficacy, safety, pharmacokinetic (PK) and immunogenicity characteristics of TRS005 via intravenous drip.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-14; most recent amendment 2025-08-21.
Trial Details
NCT Number NCT06886139
Lead Sponsor Zhejiang Teruisi Pharmaceutical Inc.
Conditions CD20-positive Diffuse Large B-Cell Lymphoma
Enrollment 139 participants
Start Date 2025-09
Primary Completion 2027-01 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-22